Cargando…
Routine coagulation test abnormalities caused by rivaroxaban: A case report
RATIONALE: Rivaroxaban is a non-vitamin K antagonist oral anticoagulant. Current recommendations state that coagulation monitoring is not required, and neither the dose nor dosing interval requires adjustment in response to changes in coagulation parameters when rivaroxaban is used for approved indi...
Autores principales: | Song, Zikai, Wu, Haidi, Cao, Hongyan, Yang, Shuo, Tang, Minglong, Qin, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250517/ https://www.ncbi.nlm.nih.gov/pubmed/30407322 http://dx.doi.org/10.1097/MD.0000000000013104 |
Ejemplares similares
-
Rivaroxaban treatment for young patients with pulmonary embolism (Review)
por: Wu, Haidi, et al.
Publicado: (2020) -
Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature
por: Wu, Hai-Di, et al.
Publicado: (2019) -
Nephrotic syndrome with acute pulmonary embolism in young adults: Two case reports
por: Song, Zikai, et al.
Publicado: (2018) -
Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)
por: Song, Zi-Kai, et al.
Publicado: (2020) -
Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report
por: Zhou, Huanyu, et al.
Publicado: (2019)